Initial toxicity, QoL outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated vs. standard fractionated PT for low-risk prostate cancer
A multi-center prospective phase 3 randomized trial aimed to identify differences in toxicity and quality-of-life outcomes between standard fractionation and...